NCT06970106 - Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

January 1, 2027

Conditions

OPA1 Gene MutationAutosomal Dominant Optic AtrophyHereditary Optic AtrophiesKjer Optic Atrophy

Interventions

DRUG

PYC-001

PYC-001 is a peptide-phosphorodiamidate morpholino oligonucleotide administered intravitreally

Trial Locations (2)

RECRUITING

Save Sight Institute - Sydney Eye Hospital, Sydney

RECRUITING

Cerulea Clinical Trials, East Melbourne